• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 30, 2015

View Archived Issues

Mereo launches with three Novartis drugs, $119M series A round

LONDON – Mereo Biopharma Ltd. has raised $119 million in a series A round after agreeing to acquire three clinical-stage programs from Novartis AG. Read More

'Awesome' numbers for Gilead, Q2 earnings beat top- and bottom-line

Following Biogen Inc.'s lackluster report last week, Gilead Sciences Inc. is getting the second quarter biotechnology earnings season back on track, reporting its financial results after the markets closed on Tuesday. Read More

Ariad strikes synthetic royalty deal with PDL to back cancer programs

Ariad Pharmaceuticals Inc. agreed to pay mid-single-digit royalties on futures sales of Iclusig (ponatinib) to PDL Biopharma Inc. in exchange for up to $200 million in financing intended to accelerate testing of brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor it is developing to treat non-small-cell lung cancer (NSCLC), and to continue its ongoing initiatives supporting both drugs. Read More

China regulation reform coming: Fee hikes, import guidelines just the start

HONG KONG – The CFDA is getting closer to completing a new revision of the country's Pharmaceutical Administration Law. After drastically increasing the registration fees for pharmaceuticals this year, the CFDA is now soliciting opinions on a draft guideline for the registration inspection of imported pharmaceutical products. Read More

China health care push creating opportunities for Taiwan market

TAIPEI, Taiwan – China's fast-growing health care sector presents excellent opportunities for industry collaboration for overseas companies. And Taiwan, with its existing cultural, language and business ties with China, is particularly well placed to take advantage of those conditions. Read More

Regulatory front

The World Health Organization (WHO) and other international organizations are calling on vaccine makers to increase production of meningitis C vaccines by 5 million doses before the 2016 meningitis season starts in January. Read More

Stock movers

Read More

Financings

Dermira Inc., of Menlo Park, Calif., filed with the SEC to raise up to $97.8 million in a public offering, though the number of shares and share price have not yet been disclosed. Read More

Earnings

The Medicines Co., of Parsippany, N.J., reported worldwide net revenue of $90.5 million for the second quarter, a significant drop from the $183.8 million reported for the same period in 2014, which the company attributed to purchasers continuing to hold out for generic versions of anticoagulant Angiomax (bivalirudin). Read More

Other news to note

Bellerophon Therapeutics Inc., of Hampton, N.J., expanded its license agreement with Dublin-based Mallinckrodt plc division Ino Therapeutics LLC, allowing Bellerophon to develop Inopulse, a drug-device combination system designed to reduce pulmonary hypertension (PH), for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic PH, PH associated with sarcoidosis and PH associated with pulmonary edema from high altitude sickness. Read More

In the clinic

Kalobios Pharmaceuticals Inc., of South San Francisco, said the FDA cleared the investigational new drug application for its anti-granulocyte macrophage colony-stimulating factor, or GM-CSF, monoclonal antibody, KB003, enabling the company to initiate its open-label phase I study to evaluate safety, pharmacokinetics and clinical activity in previously treated patients with chronic myelomonocytic leukemia. Read More

Appointments and advancements

Gtx Inc., of Memphis, Tenn., named Diane C. Young vice president, chief medical officer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe